Status:
COMPLETED
Immune Failure in Critical Therapy (INFECT) Study
Lead Sponsor:
University of Edinburgh
Collaborating Sponsors:
Technology Strategy Board, United Kingdom
Becton, Dickinson and Company
Conditions:
Sepsis
Septic Shock
Eligibility:
All Genders
16+ years
Brief Summary
Patients admitted to intensive care units (ICU) are at high risk of developing secondary infections, and this is in part due to dysfunction or failure of their 'germ killing' functions (the immune sys...
Eligibility Criteria
Inclusion
- Age \>16 (\>18 in England)
- Requiring level 3 care (i.e. requiring invasive support of respiratory system alone, or two or more other organ systems (haemofiltration, inotropes/vasopressors)
- Predicted to remain in ICU for at least 48 hours,
Exclusion
- Not expected to survive for a further 24 hours
- Known or suspected ICU-acquired infection at time of screening (non-ICU acquired nosocomial infection - i.e. non-ICU healthcare associated infection is NOT and exclusion)
- Known inborn errors of immune function
- Immunosuppression (corticosteroids up to 400mg hydrocortisone equivalent daily dose permitted)
- HIV infection
- Pregnancy
- Previously enrolled in the study
Key Trial Info
Start Date :
July 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
168 Patients enrolled
Trial Details
Trial ID
NCT02186522
Start Date
July 1 2014
End Date
January 1 2016
Last Update
October 26 2016
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Infirmary of Edinburgh
Edinburgh, United Kingdom, EH16 4SA
2
Western General Hospital
Edinburgh, United Kingdom, EH4 2XU
3
St Thomas' Hospital
London, United Kingdom, SE1 7EH
4
Sunderland Royal Hospital
Sunderland, United Kingdom, SR4 7TP